J Bruchfeld
Overview
Explore the profile of J Bruchfeld including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
353
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Folkesson E, Froberg G, Sundling C, Schon T, Sodersten E, Bruchfeld J
J Infect Dis
. 2025 Mar;
PMID: 40044585
Background: Xpert MTB-Host Response (MTB-HR) has reached WHO test targets for pulmonary tuberculosis (PTB) with high bacillary loads. Our aim was to investigate the contribution of MTB-HR as a non-sputum,...
2.
Kirakosyan O, Reimann M, Andersen A, Bjarnason A, Bakos A, Dyrhol-Riise A, et al.
IJTLD Open
. 2025 Feb;
2(2):101-106.
PMID: 39959402
Background: Anecdotal information suggests that clinical practice regarding the use of putative hepatoprotective agents in TB treatment varies across countries in the WHO European Region. Methods: Between November 2023 and...
3.
Dahl V, Burke A, Floe A, Bruchfeld J, Schon T, Wejse C, et al.
Int J Tuberc Lung Dis
. 2024 Apr;
28(4):212-213.
PMID: 38563342
No abstract available.
4.
Visca D, Centis R, Pontali E, Zampogna E, Russell A, Migliori G, et al.
Int J Tuberc Lung Dis
. 2023 Sep;
27(10):729-741.
PMID: 37749839
The aim of these clinical standards is to provide guidance on 'best practice' care for the diagnosis, treatment and prevention of post-COVID-19 lung disease. A panel of international experts representing...
5.
Singh K, Carvalho A, Centis R, D Ambrosio L, Migliori G, Mpagama S, et al.
Int J Tuberc Lung Dis
. 2023 Jun;
27(7):506-519.
PMID: 37353868
Adverse effects (AE) to TB treatment cause morbidity, mortality and treatment interruption. The aim of these clinical standards is to encourage best practise for the diagnosis and management of AE....
6.
Akkerman O, Duarte R, Tiberi S, Schaaf H, Lange C, Alffenaar J, et al.
Int J Tuberc Lung Dis
. 2022 Jun;
26(7):592-604.
PMID: 35768923
The aim of these clinical standards is to provide guidance on 'best practice´ for diagnosis, treatment and management of drug-susceptible pulmonary TB (PTB). A panel of 54 global experts in...
7.
Wikell A, Jonsson J, Dyrdak R, Henningsson A, Eringfalt A, Kjerstadius T, et al.
J Clin Microbiol
. 2021 Sep;
59(12):e0137021.
PMID: 34550805
Quantiferon-TB Gold Plus (QFT-Plus) is an interferon gamma release assay used to diagnose latent tuberculosis (LTB). A borderline range (0.20 to 0.99 IU/ml) around the cutoff (0.35 IU/ml) has been...
8.
Koirala S, Borisov S, Danila E, Mariandyshev A, Shrestha B, Lukhele N, et al.
Pulmonology
. 2021 Mar;
27(5):403-412.
PMID: 33753021
The World Health Organization (WHO) recommends countries introduce new anti-TB drugs in the treatment of multidrug-resistant tuberculosis. The aim of the study is to prospectively evaluate the effectiveness of bedaquiline...
9.
Casco N, Jorge A, Palmero D, Alffenaar J, Fox G, Ezz W, et al.
Int J Tuberc Lung Dis
. 2021 Jan;
25(1):78-80.
PMID: 33384052
No abstract available.
10.
Shedrawy J, Jansson L, Bruchfeld J, Lonnroth K
Int J Tuberc Lung Dis
. 2020 Apr;
24(4):461-463.
PMID: 32317072
No abstract available.